CPL @1099 (95.7%) on 22-jan-2018 [ "_ is the first drug" "_ is usually taken once a day" "_ is an oral anticoagulant" "_ is a new medication" "_ is usually not prescribed for" "new drug called _" "_ is dialyzable" "Overdose of _" ] using dabigatran
CPL @1104 (81.5%) on 18-mar-2018 [ "_ is the first drug" "_ is usually taken once a day" "_ is an oral anticoagulant" "drug called _" "_ has a longer half-life" "_ is a new medication" "_ is an anticoagulant" "_ is usually not prescribed for" "_ is dialyzable" "_ was not mutagenic" "_ is primarily excreted in" "Overdose of _" ] using dabigatran
SEAL @536 (99.8%) on 22-mar-2012 [ 123456789 ] using dabigatran
OE @832 (97.8%) on 18-apr-2014 [ ] using dabigatran
CPL @1104 (97.1%) on 18-mar-2018 [ "medicine such as _" "_ is the generic name" "prodrug of _" "second dose of _" "pharmacokinetics of _" "adverse events associated with _" "drug called _" "clinical efficacy of _" "anticoagulation with _" "patients treated with _" "common side effect of _" "anticoagulant effect of _" "anticoagulants such as _" "concomitant use of _" "Mothers It is not known whether _" "lower dose of _" "renal clearance of _" "clinical trial of _" "you stop taking _" "drugs like _" "controlled trials of _" "patient taking _" "patients taking _" "potential side effects of _" "off-label uses of _" "half-life than _" "clinical trials of _" "safety profile of _" "side effects of _" "you are taking _" "dosage of _" "medication , such as _" "dosages of _" "possible side effects of _" "new concern about _" "normal dose of _" "medications , such as _" "_ is excreted in" "Drug interactions with _" "higher dose of _" "dose of _" "adverse reactions associated with _" "_ reduced the risk" "Drug Administration approved _" "long-term side effects of _" "drugs including _" "patients were treated with _" "off-label use of _" "inhibitors such as _" "Administration approved _" "safety of oral _" "pharmacokinetic profile of _" "recommended dose of _" "FDA approval of _" "reactions associated with _" "prescriptions for _" "FDA has approved _" "_ are drugs" "side effect with _" "therapy with _" "patient receiving _" "patients prescribed _" "adverse events with _" "absolute bioavailability of _" "treatment with _" "anticoagulant effects of _" "doses of _" "DDD-mg dose of _" "inhibitors , including _" "drug interactions with _" "patients given _" "medication called _" "FDA approved _" "medication like _" "anticoagulants , such as _" "drug known as _" "pill called _" "higher doses of _" ] using dabigatran
relations
NELL has only weak evidence for items listed in grey